Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Imbio Partners with MEDICAL-NOTE to Expand Image Analysis Tool Offering to Clinicians across Italy

Imbio, a medical imaging artificial intelligence (AI) provider for chronic lung and cardiothoracic diseases, and MEDICAL-NOTE, an applications and software company for surgical procedure management and multi-disciplinary team communication, announced they are partnering to expand access to Imbio AI technologies across Italy. The partnership will provide valuable quantitative imaging data to surgeons, pulmonologists, radiologists, and their patients directly through MEDICAL-NOTE applications.

Imbio technology delivers quantitative and personalized imaging analysis for patients suffering from both acute and chronic diseases. The fully automated technology transforms chest CT studies into rich visual maps of a patient’s lungs with accompanying reports that provide detailed data on the type and extent of abnormalities found in the images. Imbio algorithms support multiple clinical initiatives such as lung cancer screening, smoking cessation, surgical planning and pulmonary embolism management programs, and can be used in clinical trials and academic research for numerous diseases.

Recommended AI News: Circle Integrates With Plaid To Simplify ACH Payments

“Imbio is excited to embark on this journey with MEDICAL-NOTE to not only expand our distribution, but also to integrate our algorithm outputs through their LUNG-NOTE application. Together we can help clinicians utilize the vast quantitative information obtained from patients’ diagnostic chest images for lung pathologies to ultimately drive actionable decision-making for better patient care,” said Dave Hannes, CEO at Imbio.

Related Posts
1 of 21,988

MEDICAL-NOTE simplifies daily tasks for surgeons, optimizes preoperative planning and minimizes complications through digital solutions. LUNG-NOTE will initially feature Imbio’s Lung Density Analysis (LDA) and Lung Texture Analysis (LTA) allowing clinicians to quickly visualize a patient’s lungs to support diagnosis and treatment decisions for a variety of patient conditions including COPD/emphysema and fibrotic disease.

Recommended AI News: Huobi Ventures Announces Investment in Project SEED, a One-Stop, Play-to-Earn GameFi Platform

“We are proud to announce this partnership with Imbio. Our mission to digitize the field of Medicine has always been clear to us. By integrating both Imbio’s Lung Texture and Lung Density Analysis products, we are now moving MEDICAL-NOTE to the next level,” said Stefano Palma, General Manager at MEDICAL-NOTE.

Teams from both companies will be exhibiting and presenting at the 37th Italian Society of Thoracic Surgery (SICT) National Congress in L’Aquila, Italy from September 30th through October 2nd.

Recommended AI News: PortAventura World Becomes the First Theme Resort to Accept Bitcoin as Payment at the Hotels Next Season

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.